Tag: Cancer Immunotherapy and Biomarkers
Combination therapy showed a temporary response in metastatic DDCS
—
in OncologyCase report demonstrates promising response to pembrolizumab and pazopanib combination therapy in metastatic dedifferentiated chondrosarcoma, highlighting emerging systemic treatment options.
Short-course anti-TB therapy followed regression of reactivated TB focus
—
in MedicineCase report of ICI-induced TB reactivation managed with short-course anti-TB therapy followed by continued checkpoint inhibitor monotherapy, suggesting personalized management alternatives to.
FMT with immunotherapy showed activity in NSCLC and melanoma
—
in OncologyPhase 2 trial: donor FMT plus first-line ICI in NSCLC and melanoma showed high ORRs and implicates loss of specific bacterial taxa in association with response.
